ライフサイエンスコーパス: beta-2 adrenoceptor

1 to exhibit a high degree of selectivity for beta 2-adrenoceptors.

2 antly via activation of the subpopulation of beta 2-adrenoceptors.

3 rmation of such shape-shifting system as the beta(2)-adrenoceptor.

4 positively modulate agonist affinity at the beta(2) -adrenoceptor.

5 P 20712A, indicating that fenoterol acts via beta(2)-adrenoceptors.

6 determine the autophagy effect of sustained beta(2) -adrenoceptor activation in rodents with neuroge

7 ay(-1) ) abolishes the beneficial effects of beta(2) -adrenoceptor activation on the skeletal muscle

8 Sustained beta(2) -adrenoceptor activation using Formoterol (10 mu

9 urther supporting an autophagy mechanism for beta(2) -adrenoceptor activation, skeletal muscle-specif

10 Regional infusions of beta(2)-adrenoceptor (ADRB2) agonist have generally show

11 Dietary sodium affects function of the beta-2 adrenoceptor (ADRB2).

12 hat inhaled corticosteroid (ICS)/long-acting beta (2)-adrenoceptor agonist (LABA) combination therapy

13 epithelial cells, formoterol, a long-acting beta (2)-adrenoceptor agonist (LABA), enhanced the expre

14 h Combivent, a combination of a short-acting beta(2)-adrenoceptor agonist (salbutamol) and a short-ac

15 n this study, we examined the effects of the beta(2)-adrenoceptor agonist, fenoterol, on the expressi

16 ition, application of albuterol, a selective beta(2)-adrenoceptor agonist, significantly blocked caps

17 pression changes produced by the long-acting beta (2)-adrenoceptor agonists (LABAs) salmeterol, indac

18 beta(2) -adrenoceptor agonists improve autophagy and re-

19 In the treatment of COPD, long-acting beta(2)-adrenoceptor agonists (LABAs) given twice daily

20 studies have demonstrated that although most beta(2)-adrenoceptor agonists activate both G(s) and G(i

21 on of topical long-acting dual D(2)-receptor/beta(2)-adrenoceptor agonists for the treatment of chron

22 xyquinolinone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and eva

23 capsaicin selectively activates nociceptors, beta(2)-adrenoceptor agonists may have clinical utility

24 vidence that long-acting agents, such as the beta(2)-adrenoceptor agonists salmeterol and formeterol,

25 s relative to a series of clinical reference beta(2)-adrenoceptor agonists.

26 isoproterenol (an agonist of the Gs-coupled beta(2)-adrenoceptor) alone or in combination.

27 s alpha coupled much more efficiently to the beta 2 adrenoceptor and the D1 dopamine receptor as dete

28 R-Galphas19cha18 was recruited to Gs coupled beta(2) -adrenoceptor and EP(2) receptors in an agonist-

29 and examined its ability to couple with the beta(2) adrenoceptor and to activate adenylyl cyclase.

30 otein kinase A phosphorylation status of the beta(2) adrenoceptor and, thereby, its ability to switch

31 wo different G(s)-coupled receptor pathways, beta(2)-adrenoceptors and prostanoid receptors that are

32 nephrine effect was blocked by the selective beta(2)-adrenoceptor antagonist, ICI 118,551, but not by

33 negative inotropic effects of the selective beta(2)-adrenoceptor (AR) antagonist ICI 118,551 in myoc

34 The C terminus of the beta(2)-adrenoceptor (AR) interacts with G protein-coupl

35 ch represents approximately 25% of the total beta(2)-adrenoceptor (AR) population as determined with

36 lioma cell line, which expresses beta 1- and beta 2-adrenoceptors at a ratio of 80:20, was used to in

37 osttranslational modifications (PTMs) of the beta-2 adrenoceptor (B2AR) play a fundamental role in re

38 nase A (PKA)-mediated phosphorylation of the beta(2)-adrenoceptor, because the R,R isomers also marke

39 Beta(2)-adrenoceptor (beta(2)-AR) agonists are very effe

40 Chronic regular use of beta(2)-adrenoceptor (beta(2)-AR) agonists in asthma is

41 MA, linked by a C9 polymethylene chain to a beta(2)-adrenoceptor (beta(2)AR) agonist moiety, represe

42 The beta(2)-adrenoceptor (beta(2)AR) couples to the G-protei

43 examine the architecture of agonist-occupied beta(2)-adrenoceptor (beta(2)AR) in complex with the het

44 Endothelial beta(2)-adrenoceptor (beta(2)AR) stimulation increases n

45 The beta(2)-adrenoceptor (beta(2)AR) was one of the first Fa

46 beta(2)-Adrenoceptors (beta(2)-AR) are prototypical G-pr

47 Activation of beta(2)-adrenoceptors (beta(2)ARs) causes airway smooth

48 NHERF1 is crucial to beta-2-adrenoceptor (beta(2)AR)-mediated activation of c

49 carinic acetylcholine receptors (mAChRs) and beta-2-adrenoceptors (beta2ARs) are important regulators

50 improvements in inhaled corticosteroids and beta(2)-adrenoceptor bronchodilators.

51 terol exhibits sustained agonist activity at beta 2-adrenoceptors, but not beta 1-adrenoceptors, expr

52 ptor polymorphism is associated with altered beta 2-adrenoceptor expression in asthma patients.

53 that anthracycline chemotherapy up-regulated beta(2)-adrenoceptor expression and amplified receptor s

54 PDGFRalpha(+) cells also express beta(2) -adrenoceptor gene transcripts, Adrb2.

55 Polymorphisms in the gene encoding the beta(2)-adrenoceptor have been associated with interindi

56 ent of the affinity of unlabeled ligands for beta(2) -adrenoceptor IAM site.

57 eptors and of salmeterol at both beta 1- and beta 2-adrenoceptors in an attempt to determine whether

58 Salmeterol was found to persist at beta 2-adrenoceptors in C6 cells despite washing cell mo

59 ydroxydopamine or genetic deletion of NGF or beta(2)-adrenoceptor in tumor cells enhanced the therape

60 these studies demonstrate that activation of beta(2)-adrenoceptors in dental pulp significantly reduc

61 rve data from cells subjected to fractional, beta (2)-adrenoceptor inactivation determined that PDE4

62 drenoceptors, arrestin-biased signalling via beta(2)-adrenoceptors is a molecular mechanism proposed

63 ies have suggested that polymorphisms of the beta 2-adrenoceptor may influence the desensitisation in

64 mpared the temporal characteristics of these beta(2) adrenoceptor-mediated cAMP and CRE-gene transcri

65 any beta antagonists do stimulate very small beta(2) adrenoceptor-mediated cAMP responses, but these

66 ion of ATG7 blunts the beneficial effects of beta(2) -adrenoceptor on skeletal muscle proteostasis an

67 ration of action of salmeterol was unique to beta 2-adrenoceptors or, as with formoterol, resulted fr

68 y inhibited GTP gamma S/GppNHp-, AlF(4)(-)-, beta(2)-adrenoceptor plus GTP-, cholera toxin plus GTP-,

69 We have found preliminary evidence that beta 2-adrenoceptor polymorphism is associated with alte

70 termination of their activities at the human beta(2)-adrenoceptor receptor showed symmetrical substit

71 Exchange of Asn-312 and Leu-311 in the beta 2 adrenoceptor resulted in nonfunctional proteins,

72 ore, the sustained activity of salmeterol at beta 2-adrenoceptors seems to be unique and does not res

73 d the vasodilatation, whereas 0.1 mum of the beta(2) -adrenoceptor selective antagonist ICI-118,551 h

74 G(i) proteins, fenoterol, a full agonist of beta(2)-adrenoceptor, selectively activates G(s) protein

75 tophagy as a critical downstream effector of beta(2) -adrenoceptor signaling pathway in skeletal musc

76 esting autophagy as a downstream effector of beta(2) -adrenoceptor signaling pathway.